English
Home > Products > CAS:58-22-0

China CAS:58-22-0 Manufacturer

To be a result of ours specialty and repair consciousness, our corporation has won a good popularity amid consumers everywhere in the environment for CAS:58-22-0, We warmly welcome prospects, organization associations and mates from everywhere in the earth to get in touch with us and request cooperation for mutual benefits.
CAS:58-22-0, With high quality, reasonable price, on-time delivery and customized & customized services to help customers achieve their goals successfully, our company has got praise in both domestic and foreign markets. Buyers are welcome to contact us.

Related Products

Hot Products

  • Methylprednisolone Hemisuccinate

    Methylprednisolone Hemisuccinate

    For Methylprednisolone Hemisuccinate, we have EP, USP and CP specification. DMF and WC available.

    CAS:2921-57-5

  • Pregnenolone Acetate

    Pregnenolone Acetate

    Pregnenolone Acetate

    CAS:1778-02-5

  • Lasmiditan Succinate

    Lasmiditan Succinate

    Lasmiditan Succinate has In-house specification. DMF approved.

    CAS:439239-92-6

  • Luliconazole

    Luliconazole

    Luliconazole has In-house specification, DMF approved.

    CAS:187164-19-8

  • Epiandrosterone

    Epiandrosterone

    Epiandrosterone is a steroid hormone with weak androgenic activity. It is a metabolite of testosterone and dihydrotestosterone (DHT).

    CAS:481-29-8

  • Abiraterone

    Abiraterone

    Abiraterone is a steroidal cytochrome P 450 17α-hydroxylase-17,20-lyase inhibitor (CYP17), It is used in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer (prostate cancer that is resistant to medical or surgical treatments that lower testosterone and has already spread to other parts of the body) and metastatic high-risk castration-sensitive prostate cancer.

    CAS:154229-19-3

  • Related Blog
  • Reviews

  • 2019 CPhI China Exhibition Shanghai

    June 2019
    CPhI is the undisputed leader in the pharmaceutical industry. CPhI China offers a key access point to the second largest pharma market in the world. The exhibition features over 3,000 companies and incorporates various API showcases like bioLIVE, iCSE, NEX and FDF, creating a comprehensive platform that connects the entire pharmaceutical industry chain in the Asian-Pacific region.

  • 2021 API Exhibition Guangzhou

    May 2021
    API China is a well-established comprehensive pharmaceuticals and chemicals show in Chinese pharmaceutical industry. With more than 40 years’ experience in China, it has been a well-known celebration for all parties involved in Chinese Pharmaceutical market.

  • 2022 API Exhibition Qingdao

    August 2022
    Founded by China National Medical Control Bureau (the predecessor of NPMA) in 1968.
    Gathering 97% of Top 100 Chinese pharmaceutical enterprises.
    99% manufactures meets the requirements of GMP.
    Supported by numerous powerful associations in China: CCFDIE, CPIA, CBPIA, CATCM, CNMA, CNPPA, etc.

  • Welcome to CPhI Korea 2024

    CPhI Korea 2024 will be held at COEX, Seoul Hall A from August 27 to 29, our booth number is M27.

  • 2025 Corporate Exhibition Calendar Officially Released !

    Our 2025 Exhibition Calendar has been announced! Come meet our team and explore new business opportunities.We look forward to seeing you there!

  • How Can Intermediates Category Solutions Streamline Your Production Process

    As someone who has spent over two decades navigating the complexities of industrial production, I've seen firsthand how bottlenecks in the middle stages can derail entire operations. That’s why I was particularly impressed when I began working with solutions from the Intermediates Category. For any production manager, finding tools that seamlessly integrate and accelerate the core of your workflow is the ultimate goal. This is where the strategic approach from Humanwell truly shines, offering a refined path to efficiency that many of us have been searching for.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept